Preliminary Safety, Pharmacokinetics, and Lipid Lowering Effects of the Liver-Targeted Liver X Receptor (LXR) Inverse Agonist TLC-2716 in Healthy Volunteers (AHA 2023, Poster #Mo3209)
OrsoBio team members collaborated with Professor Takebe in his pioneering study in Cell on the first use of en masse human liver organoids to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.
